We propose that calcitonin, secreted in response to the intake of food, aids in routing calcium, obtained by intestinal absorption, into bone fluid. Here calcium is temporarily stored in combination with phosphate for return to the extracellular fluid (blood) during intervals between oral intakes of calcium. The net result is a conservation of calcium postprandially and a decrease in parathyroid hormone-induced bone destruction during subsequent fasting periods. Evidence for this postulate is provided in the following six sequential steps from the time a calcium-containing meal is consumed until that portion of calcium stored in bone fluid is utilized during fasting periods to aid in plasma calcium maintenance. This labile storage form of calcium is the first to be utilized during fasting periods. In the absence of partial disruption of this storage mechanism, rapid development of pathological bone conditions would not be expected because PTH action permits the extended utilization of bone calcium for plasma calcium control. However, augmentation of osteopenic conditions could be expected if long-term low calcium intake were accompanied by a malfunction of this calcitonin-induced system for calcium storage.
The existence of calcitonin was first reported by Copp et al. (1) in 1962. In the following year it was established by Hirsch et al. (2) as a hypocalcemic pripciple, extractable from thyroid tissue. In spite of the fact that calcitonin has been found in plasma samples taken from all mammals studied (including man), its basic physiological role has remained in doubt. It has often been labeled as a "hormone in search of a function." There is, as yet, no indication that its absence from man or other mammals is life-threatening. However, it is difficult to believe that a hormone known to circulate in blood of so many different animals does not have a demonstrable role.
Calcitonin is known to be both a hypocalcemic and a hypophosphatemic agent, and at the time of its discovery it was considered to be an important regulator of plasma calcium concentration (1, 2) . Because plasma calcium levels remain in the normal range in the absence of any calcitonin-secreting tissue, this role was changed to one that characterized it as an antihypercalcemic hormone (3, 4) . This function was proposed because endogenous calcitonin secretion will prevent or decrease the hypercalcemia that follows calcium administration by intravenous infusion, intraperitoneal injection, or gavage (5, 6) . Although calcitonin acts as an antihypercalcemic agent in these nonphysiologic conditions, it is very difficult to raise the plasma calcium concentration above normal, even in thyroidectomized animals, by feeding a meal containing a high content of calcium (7, 8) . In addition, hypercalcemic conditions in man due to hyperparathyroidism, tumors, or other internal disorders are not prevented by the presence of calcitonin-secreting tissue.
The most thoroughly tested action of calcitonin has been its ability to suppress osteoclastic-induced bone resorption (9, 10) . The osteoclast's ruffled border, the metabolically active area in bone resorption, is decreased in both its amount and its activity after calcitonin administration (11) . This action of calcitonin is considered to be the primary reason for its therapeutic effectiveness in the treatment of Paget's disease.
Recent studies have demonstrated that endogenous calcitonin decreases the efflux of calcium from fluid bathing bone surfaces to the primary extracellular fluid compartment (12, 13) . This action is central in the development of the following report in which we present evidence for what we hypothesize to be an important, and possibly the primary, physiological role for calcitonin. We propose that this function of calcitonin is of physiological significance in man as well as in other mammals because supporting evidence has also been obtained from clinical studies.
SYNOPSIS OF PROPOSED PHYSIOLOGICAL
ROLE FOR CALCITONIN We propose that calcitonin, secreted in response to food entering the digestive tract, stimulates rapid storage of a portion of the absorbed calcium in bone fluid in a readily available form. This storage is a separate, distinct process from that of the more stable adsorption of calcium on bone surfaces. The calcium stored in bone fluid is present in a labile (metastable) form which is kept from being transformed to hydroxyapatite crystals by the presence of a mineralization inhibitor. Upon cessation of calcium absorption from the gut and the decrease in circulating calcitonin levels, the stored calcium is gradually returned to the extracellular fluid. This process decreases postprandial calcium loss in the urine and supplies calcium to maintain plasma concentrations during fasting periods. The net result permits a decrease of parathyroid hormone (PTH) secretion during fasting periods so that its bone resorptive activity can be minimized. After extended periods of time, any deficiency or failure in this storage process could aggravate conditions of osteopenia caused by low dietary calcium intake.
The suggested site for calcium storage in bone fluid is illustrated in a diagram in Fig. 1 and in electron micrographs of the shaft of the tibia fixed in lanthanum in Fig. 2 . Lanthanum replaces calcium, thereby slowing deposition of the colloid. Fig.  3 provides calcium "flow" diagrams for both thyroid-intact and thyroidectomized individuals to illustrate the differences that Abbreviation: PTH, parathyroid hormone.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. (14, 15) . There is recent evidence that, in the rat, plasma calcitonin levels are increased after feeding (8, 16, 17) . This has also been reported to occur in man but, because of conflicting evidence, cannot be considered to be established (18) . It is important to point out that, in rats conditioned to a specific feeding schedule, plasma calcium concentrations decrease slightly during the feeding process before an increase in plasma calcitonin can be identified (16, 19) . The situation is different in man, in whom it has been reported that calcitonin secretion or injection during the feeding process actually prevented rather than caused a postprandial decrease in plasma calcium concentrations (20 (27) . From studies in both man and the rat we concluded that, in thyroidectomized individuals, postprandial renal calcium excretion was primarily a reflection of the amount of calcium ingested during the immediate past meal. However, in thyroid-intact individuals, the amount of calcium in the urine was influenced by the amount of calcium consumed on the preceding day (27, 28 (27 (40) (41) (42) carried out in our laboratories with 32P and 45Ca as tracers. The interpretation of the data was based on specific effects of PTH and calcitonin on plasma radioisotope specific activities. Discussion of experimental tracer procedures is beyond the scope of this report, but results of these studies (37-39) permitted the conclusion that bone rather than soft tissue was the most probable site of deposition of the phosphate leaving plasma after calcitonin injection.
A recent study (37) utilizing 32P as a tracer demonstrated that, when administered with PTH, calcitonin augmented the decrease in plasma phosphate but did not either increase or decrease the PTH-induced phosphaturia. The ability of calcitonin to override the PTH-induced changes in plasma 32p specific activity allowed us to conclude that calcitonin prevented the loss of phosphate from bone fluid, which occurred when PTH was given alone, thereby holding phosphate in bone fluid.
Our studies on effects of these two hormones on plasma phosphate concentrations have led to the conclusion that one of the results of postprandial calcitonin secretion is the conservation of bone fluid phosphate. The two hormones acting in concert postprandially direct the new supplies of calcium absorbed from the intestines into bone fluid, which at that time is maintained maximally with phosphate.
5. Storage of Calcium with Phosphate Occurs in Bone Fluid or Near the Surfaces of Bone As the Result of the Calcitonin-Induced Postprandial Sequence of Events. Evidence has accumulated for the formation of a calcium phosphate colloid in bone fluid postprandially when calcitonin-secreting tissue is present. In order for this to occur, bone lining cells and osteocytes near bone surfaces must respond rapidly to both calcitonin and PTH. Morphological changes in these cells were first reported by Matthews et al. (43) and have been confirmed in a series of reports (44) (45) (46) . Sufficient evidence now exists to convince us that these ai ! the cells that control calcium fluxes between bone fluid and blood and are the cells that furnish the metabolic stimulus for the postprandial storage of calcium with phosphate in bone fluid.
The first evidence that calcitonin injection could cause the formation of calcium phosphate compounds in bone fluid was provided by Matthews et al. (43) . Under the special conditions of their experiment this material transformed to hydroxyapatite, establishing that it contained both calcium and phosphate. Recently, by the use of various electron micrographic procedures using stains known to react with calcium or phosphate, we have been able to identify an electron-dense material in bone fluid after calcitonin injection. These procedures include fixation of rat tibia specimens with lanthanum or potassium pyroantimonate, postfixation with lead, and the use of anhydrous procedures (47) . Finally, in experiments not yet completed, we have been able to identify an electron-dense material in bone fluid of tissue samples removed from thyroid-intact rats 4 hr after they consumed a calcium-containing meal. This material was present in smaller quantities or was absent in similar preparations from thyroidectomized rats.
We believe that these studies provide evidence for the conclusion that, due to the action of calcitonin and PTH on the bone lining cell/osteocyte unit, bone fluid responds to the entrance of calcium provided postprandially by the formation of a calcium phosphate colloid. This colloid does not transform into hydroxyapatite and thus is readily available for transfer back into blood.
6. This Labile Storage Form of Calcium Is the First Calcium to be Utilized During Fasting Periods, Thereby Decreasing the Amount of PTH Required to Maintain Plasma Calcium Levels. One function of this proposed calcium storage system may be to provide calcium for plasma calcium maintenance during intervals between oral intakes of calcium. 
